Harvard University’s Alfred Goldberg, Ph.D., Daniel Finley, Ph.D., and Randall King, M.D., Ph.D., Named Harvard University Scientific Co-Founders

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Proteostasis Therapeutics announced today that it has named Alfred Goldberg, Ph.D., and Daniel Finley, Ph.D., both Professors of Cell Biology, and Randall King, M.D., Ph.D., Associate Professor of Cell Biology, all at Harvard Medical School, as company scientific co-founders. In addition, Drs. Goldberg and King join Dr. Finley as a member of the company’s Scientific Advisory Board. The three researchers are leaders in understanding the ubiquitin-proteasome pathway, an essential mechanism for protein clearance and a major component of the Proteostasis Network that regulates protein folding, trafficking, and clearance within cells to maintain protein homeostasis.